Skip to content

A Study of Therapeutic Amplitude-modulated Electromagnetic Fields in Advanced Tumors

Treatment of Advanced Cancer With Amplitude-modulated Electromagnetic Fields of Low Intensity by Means of an Intrabuccal Probe

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00440570
Acronym
THBC001
Enrollment
2
Registered
2007-02-27
Start date
2004-10-31
Completion date
2007-12-31
Last updated
2011-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Tumor, Cancer

Keywords

cancer, electromagnetic fields, treatment

Brief summary

In vitro studies suggest that low levels of amplitude-modulated electromagnetic fields may modify cell growth. We have identified specific frequencies that may block cancer cell growth. We have developed a device delivering low levels of amplitude-modulated electromagnetic fields. The device is connected to a spoon-like coupler, which is placed in the patient's mouth during treatment. We will conduct a feasibility study consisting of three daily ambulatory treatments until disease progression.

Detailed description

Background: In vitro studies suggest that low levels of amplitude-modulated electromagnetic fields may modify cell growth. We have identified specific frequencies that may block cancer cell growth. We have developed a portable and programmable device delivering low levels of amplitude-modulated electromagnetic fields. The device is connected to a spoon-like coupler, which is placed in the patient's mouth during treatment. Methods: We will conducted a feasibility study consisting of three daily treatments. All patients with advanced solid tumors and measurable disease will be eligible, irrespective of prior treatments. Patients will be assessed with laboratory exams (complete blood count, comprehensive profile, tumor markers), imaging studies every other month for the first six months, every third month thereafter.

Interventions

DEVICELow levels of amplitude-modulated electromagnetic fields
DEVICEEmitter of low levels of amplitude-modulated electromagnetic fields

Sponsors

Barbault, Alexandre, M.S.
CollaboratorINDIV
Pasche, Boris, M.D.
Lead SponsorINDIV

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 95 Years
Healthy volunteers
Yes

Inclusion criteria

* Advanced tumor that is either metastatic or inoperable

Exclusion criteria

* Pregnancy, * Other simultaneous anticancer therapies, * ECOG performance status less than 3

Design outcomes

Primary

MeasureTime frame
Safety of daily administration of amplitude-modulated electromagnetic fields in patients with advanced cancer

Secondary

MeasureTime frame
Complete blood count, comprehensive chemistry profile, tumor markers
Tumor assessment as per RECIST criteria

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026